|1.||Komajda, Michel: 20 articles (09/2015 - 10/2005)|
|2.||Carson, Peter E: 19 articles (09/2015 - 02/2008)|
|3.||Zile, Michael R: 18 articles (09/2015 - 02/2008)|
|4.||Kahan, Thomas: 17 articles (12/2013 - 04/2002)|
|5.||Anand, Inder S: 15 articles (09/2015 - 03/2010)|
|6.||McKelvie, Robert S: 15 articles (09/2015 - 02/2010)|
|7.||Malmqvist, Karin: 15 articles (12/2013 - 04/2002)|
|8.||Parving, Hans-Henrik: 14 articles (11/2014 - 06/2002)|
|9.||Massie, Barry M: 13 articles (09/2015 - 10/2005)|
|10.||de Zeeuw, Dick: 12 articles (09/2015 - 09/2003)|
|1.||Hypertension (High Blood Pressure)
01/01/2008 - "* Furthermore, the proportion of patients with severe hypertension achieving controlled BP of < 140/90 mmHg was significantly greater at all timepoints of the trial compared with irbesartan monotherapy. "
07/01/2004 - "In conclusion, treatment of hypertension with irbesartan resulted in a significant reduction in the voltage criteria for LVH, although an effect on LVM was only seen in subjects with high baseline LVM. "
09/01/2008 - "The results showed that irbesartan administered 100 mg once daily was well tolerated in the treatment of essential hypertension and was effective in producing sustained 24-h BP control."
10/01/2005 - "The objective of this study was to test the presence of the CYP2C9*3 allelic variant in the Chinese population and to investigate the association of this variant with both metabolism and therapeutic efficacy of irbesartan on essential hypertension. "
01/01/2010 - "Data in the literature suggest that irbesartan is effective for reducing blood pressure over a 24-hour period with once-daily administration, and slows the progression of renal disease in patients with hypertension and type 2 diabetes. "
|2.||Diabetic Nephropathies (Diabetic Nephropathy)
03/01/2010 - "Irbesartan was more effective in preventing deterioration of kidney function in patients with diabetic nephropathy, being cost effective from a German perspective. "
08/01/2009 - "In addition, irbesartan has been shown to be effective in both early and late stage diabetic nephropathy. "
11/01/2014 - "Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial."
06/01/2012 - "The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression. "
06/01/2012 - "Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial."
04/01/1999 - "Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure."
10/01/2005 - "The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) is enrolling 4100 subjects with HF-PSF to evaluate whether 300 mg irbesartan is superior to placebo in reducing mortality and prespecified categories of cardiovascular hospitalizations. "
03/18/2010 - "We conducted a prospective, randomised, open-label, blinded end point (PROBE) study examining the relative efficacy of irbesartan 300 mg/day versus maximising dose of ACE inhibitor, additional to background conventional heart failure therapy. "
12/01/1997 - "Preliminary studies evaluating the efficacy of irbesartan in patients with heart failure have produced encouraging results. "
06/01/2015 - "The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction)."
11/01/2002 - "The IRMA study showed that irbesartan is more effective than conventional therapy in preventing the development of clinical proteinuria and in favoring the regression to normoalbuminuria for comparable BP control in patients with incipient nephropathy. "
12/01/1998 - "Also, patients randomized to receive the AngII receptor antagonist irbesartan for 28 d had lower proteinuria (55% change from baseline) and fractional clearance of albumin at the end of the treatment period with similar renal hemodynamic changes. "
03/01/2005 - "The Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA) Study showed that, as compared with conventional therapy, irbesartan is better at preventing the development of clinical proteinuria and at restoring normoalbuminuria for comparable BP control in patients with incipient nephropathy. "
04/01/2014 - "Irbesartan somewhat lowered blood pressure and reduced proteinuria, tubulointerstitial cell proliferation and glomerulosclerosis. "
06/01/2012 - "This rate of decline was slower with longer duration of irbesartan treatment and only partly explained by observed reductions in BP and proteinuria."
|5.||Type 2 Diabetes Mellitus (MODY)
12/01/1997 - "Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus."
12/01/1997 - "The results of the present study demonstrate that the Ang II receptor antagonist irbesartan can reduce blood pressure and ameliorate glomerular and tubulointerstitial injury in an experimental model of NIDDM."
11/01/1999 - "PRA rose in response to irbesartan more gradually in the patients with type 2 diabetes mellitus, but ultimately matched the normal response. "
11/01/1999 - "Despite the low PRA, renal perfusion rose more in response to irbesartan in type 2 diabetes mellitus (714 +/- 83 to 931 +/- 116 ml/min; P = 0.002) than normal (624 +/- 29 to 772 +/- 49 ml/min; P = 0.008). "
01/01/2004 - "In two large studies (IRbesartan MicroAlbuminuria type 2 diabetes mellitus in hypertensive patients [IRMA 2] and the Irbesartan Diabetic Nephropathy Trial [IDNT]) irbesartan exerted a renoprotective effect in hypertensive patients with type 2 diabetes at both the early and later stages of diabetic nephropathy. "
|5.||Angiotensin Receptor Antagonists
|10.||Angiotensin Receptors (Angiotensin II Receptor)
|1.||Electric Countershock (Cardioversion)
|5.||Renal Replacement Therapy (Therapies, Renal Replacement)